Late Night Study 2: End-of-Day Assessment of Asymptomatic and Symptomatic Soft Lens Wearers

NCT03871543 | Completed Results FDA Device

• 1 other identifier: CR-6290
• Study Type: interventional
• Target: 196
• Locations: 1 country
• Sites: 1

Brief Summary

This is a 2-Part, 8-Visit, single-center, open-label, bilateral and dispensing clinical study. In Part 1 (Visits 1-4) all subjects will be Test Lens 1, in Part 2 (Visits 1-4) eligible subjects will be dispensed Test Lens 2 based on their responses to the CLDEQ-8 questionnaire. Subjects scoring between 11 and 19 on the CLDEQ will not continue into Part 2

Conditions

Visual Acuity

Outcome Measures

Primary Outcomes (5)

• Lid Margin Staining (Part1: Dailies Aqua Comfort Plus)

  Lid margin staining of the upper and lower eyelids was performed in the left eye (OS) only using lissamine green. The following attributes were graded subjectively for each eyelid: Horizontal length of staining (Grade 0: \< 2mm, Grade 1: 2-4 mm, Grade 2: 5-9 mm, Grade 3: \>9 mm), and Sagittal width of staining relative to width of wiper (Grade 0: \<25%, Grade 1: 25-50 %, Grade 2: 51-75%, Grade 3: \>75%). The Average staining grade for each eyelid was also calculated which is the average of the horizontal and sagittal grades. Higher Lid Margin Staining values indicate that more staining was observed.

  14 Hours Follow-up at Visit 4

• Non-invasive Tear Break-up Time (Part1: Dailies Aqua Comfort Plus)

  NIBUT was measured in timed seconds using the Medmont topographer for the right eye (OD) only. NIBUT values are positive, where higher NIBUT times (seconds) indicate a more stable tear film.

  14 Hours Follow-up at Visit 4

• Tear Meniscus Height (Part1: Dailies Aqua Comfort Plus)

  The lower tear meniscus in the right eye (OD) only was imaged and measured in mm using optical coherence tomography (OCT). Lower TMH values indicate reduced tear quantity.

  14 Hours Follow-up at Visit-4

• Tear Film Osmolarity (Part1: Dailies Aqua Comfort Plus)

  Tear film osmolarity were collected and measured in (mOsms/L) in the right eye (OD) only using the Tearlab (Tearlab Corp.).Higher tear osmolarity values may be associated with ocular dryness. Participants were classified as symptomatic or asymptomatic based on their subjective questionnaire responses for the CLDEQ-8 questionnaire assessed after two weeks of lens wear (Visit 2). CLDEQ-8 is a validated patient-reported outcome measure assessing patient-experience of symptoms relating to contact lens dryness.

  14 Hours Follow-up at Visit 4

• Number of White Blood Cells Per Frame in Eyelid Margin (Part1: Dailies Aqua Comfort Plus)

  Images, using Confocal Microscopy were taken in both eyes for both the upper and lower eyelid in the central lid area. These images were used to determine the mean density of inflammatory white blood cells. Higher white blood cell counts may be associated with an increased inflammatory response. The number of white blood cells is a count of the number of cells 'per frame'. A frame has a fixed area of 400 x 400 microns. The average number of White Blood Cells was reported for each group.

  2-Week Follow-up (after 6 hours lens wear) at Visit 2

Secondary Outcomes (12)

• Relationship Between End of Day Comfort Scores and Tear Film Osmolarity (Part1: Dailies Aqua Comfort Plus)

  VAS, and Tear Film Osmolarity 14 Hours Follow-up at Visit 4

• Relationship Between End of Day Comfort Scores and Tear Meniscus Height (Part1: Dailies Aqua Comfort Plus)

  VAS, and TMH 14 Hours Follow-up at Visit 4

• Relationship Between End of Day Comfort Scores and Lid Margin Staining (Part1: Dailies Aqua Comfort Plus)

  VAS, and Lid Margin staining 14 Hours Follow-up at Visit 4

• Relationship Between End of Day Comfort Scores and Non-invasive Tear Break-up Time (Part1: Dailies Aqua Comfort Plus)

  VAS, and NIBUT 14 Hours Follow-up at Visit 4

• Relationship Between End of Day Comfort Scores and Density of White Blood Cells Lower Lid (Part1: Dailies Aqua Comfort Plus)

  VAS, and WBC before lens removal 6 Hours Follow-up at Visit 2

Study Arms (2)

Part 1

OTHER

All eligible subjects enrolled into Part 1 will be fit and dispensed with Test Lens 1

Device: AquaComfort Plus

Part 2

OTHER

All eligible subjects (based on CLDEQ responses) enrolled into Part 2 will be fit and dispensed with Test Lens 2 and will follow the same procedures as Part 1.

Device: Acuvue Oasys 1-Day

Interventions

AquaComfort Plus DEVICE

Test Lens 1

Part 1

Acuvue Oasys 1-Day DEVICE

Test Lens 2

Part 2

Eligibility Criteria

• Age: 18 Years - 45 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Potential subjects must satisfy all of the criteria listed to be enrolled in the study.
• They are 18-45 years of age (inclusive).
• They understand their rights as a research subject and are willing and able to sign a Statement of Informed Consent.
• They are willing and able to follow the protocol.
• They agree not to participate in other clinical research while enrolled on this study.
• They currently use daily disposable soft daily wear contact lenses (worn bilaterally) (within the last six months) which may be spherical, toric or multifocal.
• They agree to wear their lenses for at least 12-14 hours per day.
• They own a wearable pair of spectacles (by self-report).
• They have a spherical contact lens prescription in the range +6.00 to -10.00 DS (based on the calculated ocular refraction).
• They have up to a maximum of 1.00 DC of refractive astigmatism (based on the calculated ocular refraction).
• They have best corrected distance visual acuity of at least 0.20 binocularly

You may not qualify if:

• Potential subjects who meet any of the following criteria will be excluded from participating in the study:
• They have an ocular disorder which would normally contraindicate contact lens wear.
• They have a systemic disorder which would normally contraindicate contact lens wear.
• No ocular topical medications (including comfort drops) from 24 hours prior to study visits or during the wear of any study lenses.
• They are regularly using anti-inflammatory or pain medications (i.e. medication routinely used more than twice per week).
• They have had cataract surgery.
• They have had corneal refractive surgery.
• They are pregnant or breast-feeding.
• They have any infectious disease (e.g. hepatitis) or any immunosuppressive disease (e.g. HIV) or a history of anaphylaxis or severe allergic reactions.
• They are an employee or immediate family member of an employee of the clinical site (e.g. Investigator, Coordinator, Technician).
• They have taken part in any other clinical trial or research within two weeks prior to starting this study.
• History of allergy to sodium fluorescein or lissamine green.
• They have any corneal distortion e.g. as a result of previous rigid lens wear or have keratoconus.
• They any slit lamp findings of Efron Grade 3 or greater (e.g. corneal edema, corneal neovascularization, tarsal abnormalities, conjunctival injection) or findings of \< Grade 3 which in the investigator's opinion would contraindicate contact lens wear.

Sponsors & Collaborators

• Johnson & Johnson Vision Care, Inc.: lead

Study Sites (1)

The University of Manchester - Eurolens Research

Manchester, United Kingdom

Location

Limitations and Caveats

Participants were classified as symptomatic or asymptomatic based on their responses to the CLDEQ-8 questionnaire after 2-weeks of lens wear. CLDEQ is a validated questionnaire assessing patient experience of symptoms related to contact lens dryness. Total Scores were calculated by summing subjects' responses to individual items (Chalmers et al, Contact Lens \& Anterior Eye 2016, 342-352). Total scores range from 0 to 37 where higher scores indicate more dryness related to contact lens wear.

Results Point of Contact

• Title: Ross Franklin
• Organization: Johnson & Johnson Vision Care, Inc.

RFRANKL1@its.jnj.com

1 800-843-2020

Study Officials

• Johnson & Johnson Vision Care, Inc. Clinical Trial

  Johnson & Johnson Vision Care, Inc.

  STUDY DIRECTOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: GT60
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SEQUENTIAL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 4, 2019
• First Posted: March 12, 2019
• Study Start: April 1, 2019
• Primary Completion: February 3, 2022
• Study Completion: February 3, 2022
• Last Updated: May 16, 2023
• Results First Posted: May 16, 2023

Record last verified: 2023-05

Data Sharing

• IPD Sharing: Will share

Locations

GB (1)